News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The CDCCs are strategically positioned in regions identified as high-impact areas
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
iSolveSM information on demand is the result of our focus on customer relationship
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Launches collaborative centre for translational research in head and neck cancer
Subscribe To Our Newsletter & Stay Updated
